Skip Navigation

U.S. Flag

Print Print   Download Reader Download   Text Enlarge text size Reduce text size Normal text size

Go to Text Version

HHS Recovery Act Recipient Reporting Readiness Tool

Step 4. Review and Copy the Grant Awards Data

TAGGS provides some – but not all – of the data needed for the Recipient Report. Recipients are responsible for directly collecting and reporting all required data to FederalReporting.gov. Data that HHS does not currently collect are highlighted in yellow. Do not copy this highlighted information. Please enter the appropriate data for your organization in these required fields. For assistance with entering these data please contact FederalReporting.gov.

You may capture the data HHS does provide by copying data from this screen and pasting it into the reporting format of your choice, such as the Excel spreadsheet template, the XML template, or by logging into the online form. For assistance with copying and pasting these data please contact our help desk at 866-814-5703.

 

Award Detail for: Role of gangliosides in tumor progression
CHILDREN'S RESEARCH INSTITUTE
DUNS Number: 143983562
111 MICHIGAN AVENUE, NW
WASHINGTON, DC 20010-2978
Recipient Report: Grant or Loan
Prime Recipient

<
Reporting Information
Award Type Award Number Final Report
Grant 5R01CA061010-15 Recipient responsible for this data

Award Recipient Information
Recipient DUNS Number Recipient Account Number Recipient Congressional District
143983562 Recipient responsible for this data Not Available

Award Information
Funding Agency Code Awarding Agency Code Award Date
7529 7529 06-25-2010
Amount of Award Sub Account Number for Program Source (TAS)  
$ 384,052 Recipient responsible for this data
Program Source (TAS)* CFDA Number 
750850 93.701
Total Number of Sub Awards to Individuals Total Amount of Sub Awards to Individuals
Recipient responsible for this data Recipient responsible for this data
Total Number of Payments to Vendors less than $25,000/award Total Amount of Payments to Vendors less than $25,000/award
Recipient responsible for this data Recipient responsible for this data
Total Number of Sub Awards less than $25,000/award Total Amount of Sub Awards less than $25,000/award
Recipient responsible for this data Recipient responsible for this data
Award Description
DESCRIPTION (provided by applicant): Tumor progression, and particularly that of some neuroectodermal tumors (e.g., neuroblastoma and melanoma) causes most cancer-related morbidity and mortality. Thus, understanding and preventing progression is critical to developing effective cancer therapies. The synthesis and shedding of the membrane glycosphingolipids, gangliosides, has been strongly implicated by our past findings and the work of others in contributing to processes that facilitate tumor progression. Moreover, we have made significant progress in elucidating basic mechanisms in vitro by which gangliosides modulate the behavior of host cells found in the tumor microenvironment. We obtained clear evidence for the impact of ganglioside synthesis and shedding on cell signaling and on angiogenic responses of human endothelial cells, and found that pharmacological inhibition of glycosphingolipid synthesis has a striking inhibitory effect upon tumor growth. Based on these findings we hypothesize that gangliosides enhance tumor progression in vivo, and that interference with the synthesis of tumor gangliosides will impede tumor progression in vivo. However, an adequate animal model system of specific and constitutive inhibition of ganglioside synthesis in vivo has been lacking, and here we propose to fill this gap, by studying tumor progression in two different and complementary novel animal model systems that we are creating. In aim 1 we will develop two oncogene transformed ganglioside-deficient fibroblast tumor cell lines, one by GM3synthase/GM2synthase double knockout and the other by 4-OH-tamoxifen-inducible, cre-mediated deletion of glucosylceramide synthase (GCS). In aim 2 we will develop a unique ganglioside-depleted rodent tumor model by cre-mediated excision of the GCS gene in an orthotopic neuroectodermal (transgenic melanoma) tumor system in vivo. In Aim 3 we will comprehensively determine how ganglioside knockout in these ganglioside-depleted tumor systems affects tumor progression, providing the first unambiguous insights in vivo in a genetically controlled and stable system. Accomplishment of these aims will begin to elucidate the role and basic mechanisms by which gangliosides modulate tumor progression in vivo. This knowledge will lead to our ultimate goals of full delineation of the biological activity of tumor gangliosides in tumor progression and the development of novel therapeutic approaches to human cancer built upon this knowledge. PUBLIC HEALTH RELEVANCE: Understanding and prevention of tumor progression is critical for development of effective cancer therapies. The goal of the research proposed in this application is to determine exactly how production and shedding by tumor cells of a special type of lipids, named gangliosides, helps tumors to grow. The results of our studies will potentially allow modulation of ganglioside production/activity by tumors, which will in turn enable design of novel and effective treatments of cancer patients.

Project Information
Project Name or
Project/Program Title
Project Status Total Federal Amount ARRA Funds
Received/Invoiced
Role of gangliosides in tumor progression Recipient responsible for this data Recipient responsible for this data
Number of Jobs Description of Jobs Created
Recipient responsible for this data Recipient responsible for this data
Quarterly Activities/Project Description
Recipient responsible for this data
 
Activity Code (NAICS or NTEE-NPC)
1Recipient responsible for this data2Recipient responsible for this data
3Recipient responsible for this data4Recipient responsible for this data
5Recipient responsible for this data6Recipient responsible for this data
7Recipient responsible for this data8Recipient responsible for this data
9Recipient responsible for this data10Recipient responsible for this data
Total Federal Amount of ARRA
Expenditure
Total Federal ARRA
Infrastructure Expenditure
Infrastructure Contact Name
Recipient responsible for this data Recipient responsible for this data Recipient responsible for this data
Infrastructure Contact Email Infrastructure Contact Phone Infrastructure Contact Phone Ext.
Recipient responsible for this data Recipient responsible for this data Recipient responsible for this data
Infrastructure Contact Street Address 1 Infrastructure Contact Street Address 2 Infrastructure Contact Street Address 3
111 MICHIGAN AVENUE, NW Not Available Recipient responsible for this data
Infrastructure City Infrastructure State Infrastructure ZIP Code+4
WASHINGTON DC 20010-2978
Infrastructure Purpose and Rationale
Recipient responsible for this data

Primary Place of Performance
Street Address 1 Street Address 2 City
111 MICHIGAN AVENUE NW Recipient responsible for this data WASHINGTON
State Zip Code+4 Congressional District
DC 20010 98
Country  
US

Recipient Highly Compensated Officers
Prime Recipient Indication of Reporting Applicability # Officer Name Officer Compensation
Recipient responsible for this data 1 Recipient responsible for this data Recipient responsible for this data
2 Recipient responsible for this data Recipient responsible for this data
3 Recipient responsible for this data Recipient responsible for this data
4 Recipient responsible for this data Recipient responsible for this data
5 Recipient responsible for this data Recipient responsible for this data

This concludes the current search.
To begin a new search, return to the HHS Recovery Act Recipient Reporting Readiness Tool.

USE IN THE RECIPIENT REPORT

The information provided by this tool is baseline data that the Recipient should include in the Recipient Report that must be submitted to FederalReporting.gov beginning October 1, 2009. The data from this tool can be cut and pasted directly into the Recipient Report.